Hedge fund
Deep Track Capital, LP
13F for June 30, 2026, filed August 14, 2026 · SEC CIK 1856083 · Holdings history from December 31, 2021
- Reported value
- $6.9bn 92% in companies we cover
- Positions we cover
- 63 Largest GH 7.4%
- Copy, a year
- +11.5% S&P 500 +14.1%
- Copy Sharpe ratio
- 0.36 S&P 500 0.63
Historical holdings
| Issuer | Class / type | Reported value | Quantity |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC00461U105 · ACRS | COM | $49.4m | 9,345,000 |
| ALIGOS THERAPEUTICS INC01626L204 · ALGS | COM NEW | $2.6m | 444,110 |
| ALKERMES PLCG01767105 · ALKS | SHS | $209.6m | 4,000,000 |
| ALNYLAM PHARMACEUTICALS INC02043Q107 · ALNY | COM | $248.3m | 825,000 |
| ALTIMMUNE INC02155H200 · ALT | COM NEW | $58.5m | 19,250,000 |
| ALUMIS INC022307102 · ALMS | COM | $178.6m | 6,348,558 |
| ATAIBECKLEY INC04650F101 | COM SHS | $76.0m | 14,417,442 |
| AVALO THERAPEUTICS INC05338F306 · AVTX | COM NEW | $66.7m | 3,610,000 |
| AXSOME THERAPEUTICS INC.05464T104 · AXSM | COM | $171.3m | 700,000 |
| BEAM THERAPEUTICS INC07373V105 · BEAM | COM | $34.3m | 1,000,000 |
| BICARA THERAPEUTICS INC055477103 · BCAX | COM | $121.7m | 4,100,000 |
| BIOMARIN PHARMACEUTICAL INC09061G101 · BMRN | COM | $189.3m | 3,307,481 |
| CELLDEX THERAPEUTICS INC NEW15117B202 · CLDX | COM NEW | $109.4m | 2,939,151 |
| CENTURY THERAPEUTICS INC15673T100 · IPSC | COM | $23.2m | 9,462,645 |
| COGENT BIOSCIENCES INC19240Q201 · COGT | COM | $77.4m | 2,000,000 |
| COMPASS PATHWAYS PLC20451W101 · CMPS | SPONSORED ADS | $172.1m | 12,161,496 |
| CONTEXT THERAPEUTICS INC21077P108 · CNTX | COM | $4.1m | 7,419,355 |
| CORMEDIX INC21900C308 · CRMD | COM | $49.3m | 6,274,076 |
| CORVUS PHARMACEUTICALS INC221015100 · CRVS | COM | $37.2m | 2,491,939 |
| CYTOKINETICS INC23282W605 · CYTK | COM NEW | $59.6m | 700,000 |
| DEFINIUM THERAPEUTICS INC24477V105 · DFTX | COM SHS | $129.4m | 2,750,000 |
| DYNE THERAPEUTICS INC26818M108 · DYN | COM | $33.3m | 1,500,000 |
| ENANTA PHARMACEUTICALS INC29251M106 · ENTA | COM | $21.1m | 1,444,167 |
| ENLIVEN THERAPEUTICS INC29337E102 · ELVN | COM | $11.4m | 225,000 |
| GENEDX HOLDINGS CORP81663L200 · WGS | COM CL A | $48.1m | 700,000 |
| GENERATE BIOMEDICINES INC370920100 · GENB | COM SHS | $22.5m | 1,333,815 |
| GENMAB A/S372303206 | SPONSORED ADS | $155.2m | 5,650,000 |
| GENMAB A/S372303206 | SPONSORED ADSCall | $82.4m | 3,000,000 |
| GH RESEARCH PLCG3855L106 · GHRS | ORDINARY SHARES | $89.6m | 3,333,334 |
| GRAIL INC384747101 · GRAL | COM | $125.3m | 1,834,944 |
| GUARDANT HEALTH INC40131M109 · GH | COM | $509.1m | 3,393,312 |
| HARROW INC415858109 · HROW | COM | $41.2m | 969,000 |
| HEMAB THERAPEUTICS HLDGS INC423494103 · COAG | COM SHS | $132.3m | 3,602,093 |
| IMMIX BIOPHARMA INC45258H106 · IMMX | COM | $28.6m | 2,775,000 |
| IMMUNOCORE HLDGS PLC45258D105 · IMCR | ADS | $9.9m | 311,218 |
| IMMUNOVANT INC45258J102 · IMVT | COM | $359.9m | 9,341,151 |
| INVENTIVA SA46124U107 · IVA | ADS | $3.0m | 800,000 |
| IONIS PHARMACEUTICALS INC462222100 · IONS | COM | $174.4m | 2,200,000 |
| KAILERA THERAPEUTICS INC482931102 · KLRA | COMMON STOCK | $15.4m | 700,000 |
| KARDIGAN INC485925101 · KARD | COM | $14.3m | 600,000 |
| KURA ONCOLOGY INC50127T109 · KURA | COM | $21.7m | 1,978,565 |
| LB PHARMACEUTICALS INC50180M108 · LBRX | COM SHS | $108.8m | 3,352,804 |
| MANNKIND CORP56400P706 · MNKD | COM NEW | $25.6m | 6,000,000 |
| MAZE THERAPEUTICS INC578784100 · MAZE | COM | $111.4m | 3,732,569 |
| MBX BIOSCIENCES INC55287L101 · MBX | COM | $95.6m | 1,732,569 |
| MOONLAKE IMMUNOTHERAPEUTICS61559X104 · MLTX | CLASS A ORD | $136.3m | 6,999,025 |
| NEKTAR THERAPEUTICS640268306 · NKTR | COM NEW | $20.9m | 300,000 |
| NURIX THERAPEUTICS INC67080M103 · NRIX | COM | $187.7m | 7,736,455 |
| NUVALENT INC670703107 | COM | $220.2m | 1,783,322 |
| OCULAR THERAPEUTIX INC67576A100 · OCUL | COM | $193.3m | 19,686,282 |
| OLEMA PHARMACEUTICALS INC68062P106 · OLMA | COM | $18.8m | 1,500,000 |
| ORUKA THERAPEUTICS INC687604108 · ORKA | COM | $183.3m | 1,926,000 |
| PERSONALIS INC71535D106 · PSNL | COM | $53.6m | 4,000,000 |
| PROMIS NEUROSCIENCES INC74346M505 · PMN | COM SHS | $11.0m | 835,655 |
| SHATTUCK LABS INC82024L103 · STTK | COM | $25.7m | 3,706,734 |
| SOLID BIOSCIENCES INC83422E204 · SLDB | COM NEW | $35.6m | 3,565,062 |
| STRUCTURE THERAPEUTICS INC86366E106 · GPCR | SPONSORED ADS | $254.4m | 4,740,072 |
| TANGO THERAPEUTICS INC87583X109 · TNGX | COM | $131.3m | 4,200,000 |
| TARSUS PHARMACEUTICALS INC87650L103 · TARS | COM | $230.8m | 3,666,768 |
| UNITED THERAPEUTICS CORP DEL91307C102 · UTHR | COM | $67.0m | 123,616 |
| VAXCYTE INC92243G108 · PCVX | COM | $250.0m | 4,300,000 |
| VERA THERAPEUTICS INC92337R101 · VERA | CL A | $171.6m | 4,000,000 |
| VERADERMICS INC922967104 · MANE | COMMON STOCK | $245.9m | 2,000,000 |
| VERASTEM INC92337C203 · VSTM | COM NEW | $21.9m | 5,740,850 |
| VIRIDIAN THERAPEUTICS INC92790C104 · VRDN | COM | $66.0m | 3,592,740 |
| X4 PHARMACEUTICALS INC98420X202 · XFOR | COM NEW | $27.5m | 5,878,757 |
| XENCOR INC98401F105 · XNCR | COM | $9.6m | 593,551 |
How copying its 13F would have done
Reported value by quarter
View chart data
| Period | Reported value |
|---|---|
| 2021-12-31 | $1.4B |
| 2022-03-31 | $1.6B |
| 2022-06-30 | $1.5B |
| 2022-09-30 | $2.2B |
| 2022-12-31 | $2.4B |
| 2023-03-31 | $2.4B |
| 2023-06-30 | $2.2B |
| 2023-09-30 | $2.6B |
| 2023-12-31 | $3B |
| 2024-03-31 | $3.5B |
| 2024-06-30 | $3.4B |
| 2024-09-30 | $3.2B |
| 2024-12-31 | $2.7B |
| 2025-03-31 | $3.1B |
| 2025-06-30 | $3.1B |
| 2025-09-30 | $3.6B |
| 2025-12-31 | $5.6B |
| 2026-03-31 | $6.1B |
| 2026-06-30 | $6.9B |
Latest covered holdings and moves
| Company | Share of portfolio | Value | Shares | Change in shares |
|---|---|---|---|---|
| GHGuardant Health, Inc. | 7.41% | $509.1m | 3.39M | +1.6% Added |
| IMVTImmunovant, Inc. | 5.24% | $359.9m | 9.34M | −19.0% Reduced |
| GPCRStructure Therapeutics Inc. | 3.70% | $254.4m | 4.74M | +10.8% Added |
| PCVXVaxcyte, Inc. | 3.64% | $250.0m | 4.30M | 0.0% |
| ALNYAlnylam Pharmaceuticals, Inc. | 3.62% | $248.3m | 825.0K | New |
| MANEVeradermics, Inc | 3.58% | $245.9m | 2.00M | +300.0% Added |
| TARSTarsus Pharmaceuticals, Inc. | 3.36% | $230.8m | 3.67M | +1.9% Added |
| ALKSAlkermes plc. | 3.05% | $209.6m | 4.00M | +11.4% Added |
| OCULOcular Therapeutix, Inc | 2.81% | $193.3m | 19.69M | 0.0% |
| BMRNBiomarin Pharmaceutical Inc | 2.75% | $189.3m | 3.31M | +187.6% Added |
| NRIXNurix Therapeutics, Inc. | 2.73% | $187.7m | 7.74M | +21.9% Added |
| ORKAOruka Therapeutics, Inc. | 2.67% | $183.3m | 1.93M | −5.3% Reduced |
| ALMSAlumis Inc. | 2.60% | $178.6m | 6.35M | −6.3% Reduced |
| IONSIonis Pharmaceuticals Inc | 2.54% | $174.4m | 2.20M | +12.8% Added |
| CMPSCompass Pathways plc | 2.50% | $172.1m | 12.16M | 0.0% |
| VERAVera Therapeutics, Inc. | 2.50% | $171.6m | 4.00M | −2.6% Reduced |
| AXSMAxsome Therapeutics, Inc. | 2.49% | $171.3m | 700.0K | −36.4% Reduced |
| MLTXMoonlake Immunotherapeutics | 1.98% | $136.3m | 7.00M | +9.2% Added |
| COAGHemab Therapeutics Holdings, Inc. | 1.93% | $132.3m | 3.60M | New |
| TNGXTango Therapeutics, Inc. | 1.91% | $131.3m | 4.20M | +52.7% Added |
| DFTXDefinium Therapeutics, Inc. | 1.88% | $129.4m | 2.75M | −8.3% Reduced |
| GRALGrail, Inc. | 1.82% | $125.3m | 1.83M | +6.5% Added |
| BCAXBicara Therapeutics Inc. | 1.77% | $121.7m | 4.10M | +0.9% Added |
| MAZEMaze Therapeutics, Inc. | 1.62% | $111.4m | 3.73M | +7.3% Added |
| CLDXCelldex Therapeutics, Inc. | 1.59% | $109.4m | 2.94M | +128.9% Added |
| LBRXLB Pharmaceuticals Inc | 1.58% | $108.8m | 3.35M | 0.0% |
| MBXMBX Biosciences, Inc. | 1.39% | $95.6m | 1.73M | −37.2% Reduced |
| GHRSGH Research PLC | 1.30% | $89.6m | 3.33M | New |
| COGTCogent Biosciences, Inc. | 1.13% | $77.4m | 2.00M | +100.0% Added |
| UTHRUnited Therapeutics Corp | 0.97% | $67.0m | 123.6K | New |
| AVTXAvalo Therapeutics, Inc. | 0.97% | $66.7m | 3.61M | New |
| VRDNViridian Therapeutics, Inc.\de | 0.96% | $66.0m | 3.59M | +157.7% Added |
| CYTKCytokinetics Inc | 0.87% | $59.6m | 700.0K | −49.1% Reduced |
| ALTAltimmune, Inc. | 0.85% | $58.5m | 19.25M | New |
| PSNLPersonalis, Inc. | 0.78% | $53.6m | 4.00M | +33.3% Added |
| ACRSAclaris Therapeutics, Inc. | 0.72% | $49.4m | 9.35M | 0.0% |
| CRMDCormedix Inc. | 0.72% | $49.3m | 6.27M | 0.0% |
| WGSGenedx Holdings Corp. | 0.70% | $48.1m | 700.0K | New |
| HROWHarrow, Inc. | 0.60% | $41.2m | 969.0K | New |
| CRVSCorvus Pharmaceuticals, Inc. | 0.54% | $37.2m | 2.49M | 0.0% |
| SLDBSolid Biosciences Inc. | 0.52% | $35.6m | 3.57M | 0.0% |
| BEAMBeam Therapeutics Inc. | 0.50% | $34.3m | 1.00M | +21.8% Added |
| DYNDyne Therapeutics, Inc. | 0.48% | $33.3m | 1.50M | −25.0% Reduced |
| IMMXImmix Biopharma, Inc. | 0.42% | $28.6m | 2.77M | New |
| XFORX4 Pharmaceuticals, Inc | 0.40% | $27.5m | 5.88M | −7.3% Reduced |
| STTKShattuck Labs, Inc. | 0.37% | $25.7m | 3.71M | New |
| MNKDMannkind Corp | 0.37% | $25.6m | 6.00M | New |
| IPSCCentury Therapeutics, Inc. | 0.34% | $23.2m | 9.46M | −0.3% |
| GENBGenerate Biomedicines, Inc. | 0.33% | $22.5m | 1.33M | New |
| VSTMVerastem, Inc. | 0.32% | $21.9m | 5.74M | 0.0% |
| KURAKura Oncology, Inc. | 0.32% | $21.7m | 1.98M | −25.2% Reduced |
| ENTAEnanta Pharmaceuticals Inc | 0.31% | $21.1m | 1.44M | −26.2% Reduced |
| NKTRNektar Therapeutics | 0.30% | $20.9m | 300.0K | New |
| OLMAOlema Pharmaceuticals, Inc. | 0.27% | $18.8m | 1.50M | New |
| KLRAKailera Therapeutics, Inc. | 0.22% | $15.4m | 700.0K | New |
| KARDKardigan, Inc. | 0.21% | $14.3m | 600.0K | New |
| ELVNEnliven Therapeutics, Inc. | 0.17% | $11.4m | 225.0K | New |
| PMNPromis Neurosciences Inc. | 0.16% | $11.0m | 835.7K | 0.0% |
| IMCRImmunocore Holdings plc | 0.14% | $9.9m | 311.2K | −83.9% Reduced |
| XNCRXencor Inc | 0.14% | $9.6m | 593.6K | New |
| CNTXContext Therapeutics Inc. | 0.06% | $4.1m | 7.42M | 0.0% |
| IVAInventiva S.a. | 0.04% | $3.0m | 800.0K | −34.6% Reduced |
| ALGSAligos Therapeutics, Inc. | 0.04% | $2.6m | 444.1K | 0.0% |
| Company | Bought (value) | Shares |
|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | $248.3m | 825.0K |
| MANEVeradermics, Inc | $184.4m | 1.50M |
| COAGHemab Therapeutics Holdings, Inc. | $132.3m | 3.60M |
| BMRNBiomarin Pharmaceutical Inc | $123.5m | 2.16M |
| GHRSGH Research PLC | $89.6m | 3.33M |
| UTHRUnited Therapeutics Corp | $67.0m | 123.6K |
| AVTXAvalo Therapeutics, Inc. | $66.7m | 3.61M |
| CLDXCelldex Therapeutics, Inc. | $61.6m | 1.66M |
| ALTAltimmune, Inc. | $58.5m | 19.25M |
| WGSGenedx Holdings Corp. | $48.1m | 700.0K |
| TNGXTango Therapeutics, Inc. | $45.3m | 1.45M |
| HROWHarrow, Inc. | $41.2m | 969.0K |
| VRDNViridian Therapeutics, Inc.\de | $40.4m | 2.20M |
| COGTCogent Biosciences, Inc. | $38.7m | 1.00M |
| NRIXNurix Therapeutics, Inc. | $33.8m | 1.39M |
| Company | Sold (value) | Shares |
|---|---|---|
| AXSMAxsome Therapeutics, Inc. | −$97.9m | −400.0K |
| IMVTImmunovant, Inc. | −$84.2m | −2.19M |
| BBIOBridgebio Pharma, Inc. | −$62.5m | −841.4K |
| CYTKCytokinetics Inc | −$57.4m | −674.3K |
| MBXMBX Biosciences, Inc. | −$56.6m | −1.02M |
| IMCRImmunocore Holdings plc | −$51.5m | −1.62M |
| GERNGeron Corp | −$47.3m | −31.72M |
| ANIPANI Pharmaceuticals Inc | −$46.1m | −600.0K |
| JANXJanux Therapeutics, Inc. | −$16.5m | −1.19M |
| ALMSAlumis Inc. | −$11.9m | −424.0K |
| DFTXDefinium Therapeutics, Inc. | −$11.8m | −250.0K |
| DYNDyne Therapeutics, Inc. | −$11.1m | −500.0K |
| ORKAOruka Therapeutics, Inc. | −$10.3m | −108.2K |
| CBIOCrescent Biopharma, Inc. | −$8.3m | −453.7K |
| ENTAEnanta Pharmaceuticals Inc | −$7.5m | −512.7K |
| Company | Value last quarter | Shares |
|---|---|---|
| BBIOBridgebio Pharma, Inc. | $62.5m | 841.4K |
| GERNGeron Corp | $47.3m | 31.72M |
| ANIPANI Pharmaceuticals Inc | $46.1m | 600.0K |
| JANXJanux Therapeutics, Inc. | $16.5m | 1.19M |
| CBIOCrescent Biopharma, Inc. | $8.3m | 453.7K |
| LRMRLarimar Therapeutics, Inc. | $6.8m | 1.50M |
| HELPHelus Pharma Inc. | $6.3m | 1.31M |
| BLLNBilliontoone, Inc. | $3.9m | 50.0K |
| Period | Copy, a year | S&P 500 | Sharpe | S&P 500 | Biggest drop | Beta |
|---|---|---|---|---|---|---|
| Whole backtestFebruary 18, 2022 to November 2, 2026 | +11.5% | +14.1% | 0.36 | 0.63 | −45.1% | 1.11 |
| Last three yearsNovember 3, 2023 to November 2, 2026 | +23.9% | +21.8% | 0.68 | 1.16 | −45.1% | 1.13 |
| Last yearNovember 7, 2025 to November 2, 2026 | +21.8% | +14.2% | 0.70 | 0.84 | −21.6% | 0.85 |